Article Information
History
- June 28, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Ariadna Acedo-Terrades1,
- Alejo Rodriguez-Vida1,2,
- Oscar Buisan3,
- Marta Bódalo-Torruella1,
- Maria Gabarrós1,
- Miquel Clarós1,
- Nuria Juanpere4,
- Marta Lorenzo4,
- Sergio Vázquez Montes de Oca1,
- Alejandro Rios-Hoyo2,
- Cristina Carrato Moñino5,
- Tamara Sanhueza5,
- Eduardo Eyras1,6,
- Eulàlia Puigdecanet7,
- Gottfrid Sjödahl8,
- Júlia Perera-Bel1,#,
- Lara Nonell9,# and
- Joaquim Bellmunt1,10,#
- 1Hospital del Mar Research Institute (HMRI), Barcelona, Spain
- 2Medical Oncology Department, Hospital del Mar, Barcelona, Spain
- 3Urology Department, Hospital de Bellvitge, Barcelona, Spain
- 4Department of Pathology, Hospital del Mar, Barcelona, Spain
- 5Urology Department, University Hospital Germans Trias i Pujol, Badalona, Spain
- 6EMBL Australia Partner Laboratory Network at the Australian National University, Canberra Australian Capital Territory, Australia
- 7IRIS-CC & MoD Lab Research Group. Faculty of Medicine, UVic-UCC, Vic, Spain
- 8Division of Urological Research, Department of Translational Medicine, Lund University and Department of Urology, Malmö, Sweden
- 9Bioinformatics Unit, Vall d’Hebron Institute of Oncology, Barcelona, Spain
- 10Dana Farber Cancer Institute, Harvard Medical School Boston Massachusetts, USA
- ↵#co-corresponding authors jbellmunt{at}researchmar.net
Posted June 28, 2024.
Predicting response to cisplatin-based neoadjuvant chemotherapy for muscle-invasive bladder cancer: transcriptomic features outrank genomic biomarkers
